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Purpose: Noninfectious uveitis results in vision loss and ocular complications without adequate treatment.
We compared the risk of developing ocular complications between patients with noninfectious intermediate
uveitis, posterior uveitis, or panuveitis (NIIPPU) and matched controls.
Design: Retrospective analysis of insurance claims data (OptumHealth, Eden Prairie, MN; January 1,
1998eMarch 31, 2012).
Participants: Cases 18 to 64 years of age with 2 or more NIIPPU diagnoses (International Classiﬁcation of
Diseases, 9th Revision, Clinical Modiﬁcation codes) were matched 1:1 by sex, age, region, company, employ-
ment status, and index date with controls without uveitis. Patients with an ocular complication during baseline
were excluded.
Methods: Continuous eligibility for 6 months or more before the ﬁrst NIIPPU diagnosis date was required.
Risks of ocular complications developing during patients’ continuous eligibility in the study period were compared
using unadjusted Kaplan-Meier survival analysis to estimate risk of and time to complications and adjusted Cox
regression analysis to estimate hazard ratios (HRs).
Main Outcome Measures: Percentages of cases and controls who demonstrate ocular complications and
1-, 5-, and 10-year risks and HRs for each complication.
Results: Mean age of the 1769 cases and matched controls was 47 years and 47% were men; 302 cases
had persistent NIIPPU. During the study period, NIIPPU cases had a higher risk of any ocular complication
(P < 0.001); the 5-year risk of any ocular complication was 66% for patients versus 24% for controls. Speciﬁcally,
NIIPPU patients had greater 5-year risks of glaucoma (20% vs. 9%), cataract (35% vs. 13%), visual disturbance
(29% vs. 9%), blindness or low vision (5% vs. 0.5%), retinal detachment (11% vs. 0.8%), and retinal disorder
(28% vs. 2%) compared with controls. Hazard ratios indicated greater risks of ocular complications in cases
versus controls during the overall observation period (HR, 5.2 for any ocular complication; HR, 4.8 for visual
disturbance; HR, 3.2 for cataract; and HR, 2.7 for glaucoma; all P < 0.001). Hazard ratios for persistent cases
indicated even greater risks.
Conclusions: Noninfectious intermediate uveitis, posterior uveitis, or panuveitis, particularly persistent dis-
ease, is associated with a substantial risk of ocular complications. Optimal treatment initiatives remain imperative
to reduce the ocular complicationerelated burden of NIIPPU. Ophthalmology 2016;123:655-662 ª 2016 by the
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Uveitis is an umbrella term that refers to infectious or
noninfectious inﬂammation in the uveal tract and adjacent
structures of the eye, depending on the anatomic site of
maximum inﬂammation. Prevalence estimates of uveitis
vary by country, race, age, and cause of the disease. Overall
prevalence estimates in the United States, including both
infectious and noninfectious uveitis, range from 58 to 115
cases per 100 000 persons.1e3 Approximately 10% to 15%
of preventable blindness in Western countries is caused by
uveitis and associated complications.4e7 In addition, major
vision loss (deﬁned as best-corrected visual acuity 20/50) 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.has been reported in 20% to 70% of patients treated in
uveitis referral centers or academic ophthalmology
clinics.5,7,8
Uveitis is classiﬁed by the primary anatomic location of
the inﬂammation according to the Standardization of Uveitis
Nomenclature guidelines and also whether it is caused by an
infectious agent or is associated with an immune-mediated
disease.9 Anterior uveitis, which refers to inﬂammation of
the iris and ciliary body, is the most common form in
Western countries,10,11 accounting for 91% of cases in
community-based clinics and more than 50% in tertiary care655http://dx.doi.org/10.1016/j.ophtha.2015.10.028
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Ophthalmology Volume 123, Number 3, March 2016centers.8,12e15 Although less common than anterior uveitis,
noninfectious intermediate uveitis, posterior uveitis, or
panuveitis (NIIPPU) typically either is idiopathic and
comprises many well-deﬁned uveitic ocular conditions or is
associated with systemic underlying autoimmune disorders,
both of which present with varying degrees of ocular
comorbidities; these complications account for most uveitis-
related visual morbidity in these patients.5,16e18 Therefore,
the goal remains to subdue inﬂammation and to prevent
complications associated with persistent inﬂammation
complications, where the mainstay of therapy includes
corticosteroids, other immunosuppressive agents, or
both.19,20
Vision-threatening complications in patients with
NIIPPU include macular edema, cataract, glaucoma, vitre-
ous debris, and retinopathy, with macular edema remaining
the most frequently encountered structural complication of
uveitis that results in central visual impairment.5e8,15,18,21,22
In a retrospective study from 2 uveitis referral centers in the
Netherlands, 41% of patients with intermediate uveitis, 28%
with posterior uveitis, and 53% with panuveitis had cystoid
macular edema, which accounted for 41% of visual
impairment and 29% of blindness in these patients.5 In other
studies, macular edema has been estimated to be present in
85% of cases of intermediate uveitis, 35% of cases of
panuveitis, and 20% of cases of posterior uveitis, causing
up to 30% of permanent uveitis-related vision loss.7,23,24
Cataract is another signiﬁcant cause of vision loss in pa-
tients with uveitis, present in 18% to 35% of patients.7,15
Long-term corticosteroid use (systemic or local) for the
treatment of uveitis can lead to glaucoma and cataract, to
which signiﬁcant ocular morbidity can be attributed.25e27
Overall, the morbidity and burden associated with uveitis
and these complications remain a signiﬁcant cost for health
care systems.28 For the patients, there also remains a
negative effect on quality of life.28e33 To provide addi-
tional data informing the burden of disease, we aimed to
assess the risk of ocular complications in a privately insured
NIIPPU cohort in the United States compared with matched
controls without uveitis. In addition, an analysis of persis-
tent NIIPPU cases was conducted.Methods
Data Source and Patient Sample
Patients were identiﬁed using the OptumHealth (Eden Prairie, MN)
Reporting and Insights database from January 1998 through March
2012.34 The OptumHealth database includes medical and drug
claims for 16.4 million privately insured individuals in 69 self-
insured companies and represents a diversity of industry sectors,
such as ﬁnancial services, manufacturing, telecommunications,
energy, and the food and beverage industry. Available data include
employees’ beneﬁt eligibility and medical and pharmacy service
claims. The OptumHealth database is compliant with the American
Health Insurance Portability and Accountability Act; ethics
approval was not required for this study because the data analyzed
were de-identiﬁed records from an administrative insurance
database.
Patients 18 to 64 years old with a diagnosis of NIIPPU were
identiﬁed using International Classiﬁcation of Diseases, Ninth656Revision, Clinical Modiﬁcation codes for intermediate uveitis,
posterior uveitis, or panuveitis (360.12 [panuveitis], 362.12
[exudative retinopathy], 362.18 [retinal vasculitis], 363.0x [focal
chorioretinitis and focal retinochoroiditis], 363.10e13 and 363.15
[disseminated chorioretinitis and disseminated retinochoroiditis],
363.2x [other and unspeciﬁed forms of chorioretinitis and reti-
nochoroiditis], and 364.24 [Vogt-Koyanagi syndrome]). A diag-
nosis of uveitis had to be on at least 2 medical claims to conﬁrm the
presence of the condition. These codes were modiﬁed from those
used by Reeves et al35 to exclude anterior diagnoses and those
likely to be infectious. Data for the subgroup of cases with
persistent NIIPPU, deﬁned as cases with disease duration of 90
days or more and receiving standard of care such as
corticosteroids, immunosuppressant therapy, biologic therapy, or
a combination thereof, also were analyzed.9
The index date for each case was the ﬁrst diagnosis of NIIPPU.
Cases were required to have continuous eligibility (deﬁned as no
more than a 30-day gap between health plan enrollment segments)
and no preexisting ocular complications during the baseline period
(6-month period before ﬁrst NIIPPU diagnosis; incident cases were
identiﬁed during the 6-month baseline period). Potential controls
were assigned the index date of their case match. Patients with
NIIPPU with no preexisting ocular complications were matched
1:1 by sex, age, region, company, and employment status to con-
trols without a diagnosis of uveitis. The study period spanned from
the index date through the duration of continuous eligibility for
each patient (Fig 1).
Ocular Outcomes and Risk Factors
Ocular complications were identiﬁed by International Classiﬁca-
tion of Diseases, 9th Revision, Clinical Modiﬁcation codes and
included glaucoma (365.xx); cataract (366.xx); visual disturbances
(368.xx, 379.23, and 379.24), including vitreous opacities and
vitreous hemorrhage; blindness or low vision (369.xx and 360.41),
including blind hypotensive eye (phthisis bulbi); retinal detach-
ment (361.xx); and retinal disorder, including cystoid macular
degeneration (cystoid macular edema), retinal ischemia, retinal
neovascularization, macular cyst/hole/pseudohole, macular puck-
ering (epiretinal membrane), and retinal (macular) edema (362.53,
362.84, 362.16, 362.54, 362.56, and 362.83, respectively). The
primary outcome of interest was time from the index date to
the ﬁrst occurrence of each of the ocular complication events.
Time to any ocular complication was calculated as the time
from the index date to the day of the ﬁrst observed claim for
any of the ocular complications under investigation. Risk
factors and other causes relevant to each ocular complication
were identiﬁed as potential covariates based on a literature
review and were deﬁned using International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation codes36e49
(Table 1, available at www.aaojournal.org).
Statistical Analysis
Baseline characteristics were compared using univariate analyses.
McNemar’s tests were used for categorical variables and Wilcoxon
signed-rank tests were used for continuous variables. Time to
development of ocular complications during the study period was
compared using unadjusted Kaplan-Meier survival analysis and
log-rank tests. Patients without a claim for an ocular complication
during the study period were censored at the last day of follow-up
in the study period. The 1-, 5-, and 10-year risks of developing
complications were estimated using Kaplan-Meier survival anal-
ysis. Adjusted Cox proportional-hazards regression models were
used to estimate hazard ratios (HRs) for NIIPPU cases relative to
controls, adjusting for age, sex, region, and Charlson comorbidity
Figure 1. Flowchart showing study design. NIIPPU ¼ noninfectious intermediate uveitis, posterior uveitis, or panuveitis.
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ocular complication.Table 2. CaseeControl Matched Patient Characteristics at
Baseline*
Characteristics
Incident NIIPPU
Group (n [ 1769)
Persistent NIIPPU
Group (n [ 302)
Men 826 (46.7) 123 (40.7)
Age (yrs), mean (SD) 46.7 (11.4) 48.5 (10.1)
Age distribution (yrs)
18e30 189 (10.7) 20 (6.6)
31e44 502 (28.4) 71 (23.5)
45e54 547 (30.9) 114 (37.7)
55e64 531 (30.0) 97 (32.1)
Regiony
Northeast 460 (26.0) 88 (29.1)
Midwest 338 (19.1) 61 (20.2)
South 620 (35.0) 100 (33.1)
West 197 (11.1) 36 (11.9)
Unknown 154 (8.7) 17 (5.6)
Data are n (%) unless otherwise indicated.
NIIPPU ¼ noninfectious intermediate uveitis, posterior uveitis, or pan-
uveitis; SD ¼ standard deviation.
*The baseline period was deﬁned as the 6 months before the index date.
Patients and their matches with an ocular complication (i.e., retinal
detachment, retinal disorder, glaucoma, cataract, visual disturbance, and
blindness or low vision) during the baseline period were excluded from
analysis. Matching yielded identical demographic data for case and control
populations; thus, only the case data are displayed.
yThe distribution of region is reﬂective of the regional distribution of claims
data available and not the regional distribution of the condition. If the
region was unknown, the uveitis patient was matched to a control patient
with an unknown region.Results
Baseline Data
A total of 1769 NIIPPU cases with no preexisting ocular compli-
cations were identiﬁed and matched with 1769 controls without
uveitis. The mean age of the full NIIPPU sample and their matched
controls was approximately 47 years, and just under half were
men (Table 2). The mean Charlson comorbidity index score
was signiﬁcantly greater in cases versus controls (0.9 vs. 0.2;
P  0.0001; Table 3). In the comparison of selected baseline
autoimmune comorbidities and risk factors for ocular
complication between cases and controls, cases with NIIPPU had
a signiﬁcantly higher rate of autoimmune comorbidities
compared with controls (11.5% vs. 2.6%; P  0.0001).
Individual autoimmune comorbidities that were signiﬁcantly
more prevalent (P < 0.05) in the NIIPPU group at baseline were
spondyloarthritis (2.0% vs. 0.5%), sarcoidosis (2.4% vs. 0.1%),
rheumatoid arthritis (2.1% vs. 0.6%), multiple sclerosis (1.8% vs.
0.3%), systemic vasculitis (1.4% vs. 0.1%), and inﬂammatory
bowel disease (1.2% vs. 0.5%; Table 3). Prevalence of all
selected risk factors for ocular complications, except for
metabolic syndrome and migraine, was signiﬁcantly greater for
the NIIPPU cohort than for the matched controls (Table 3).
The persistent NIIPPU sample and their matched controls (n ¼
302 each) tended to be older (mean age, 48.5 years) than the full
NIIPPU sample, and fewer were men (40.7%; Table 2). Mean
Charlson comorbidity index score for persistent NIIPPU cases
(0.9) was signiﬁcantly greater than that for the matched controls
(0.2; P  0.0001; Table 3). Approximately 30% of persistent
NIIPPU cases had at least 1 autoimmune comorbidity at baseline
compared with 2% for controls (P  0.0001); spondyloarthritis,
sarcoidosis, systemic vasculitis, inﬂammatory bowel disease,
systemic lupus erythematosus, and rheumatoid arthritis were
signiﬁcantly more prevalent among persistent cases versus
controls (Table 3). Similar to the full NIIPPU cohort, many of
the selected risk factors for ocular complications were more
common among the persistent NIIPPU cases versus controls,
including age-related macular degeneration, diabetes or diabeticretinopathy, vitreous degeneration or detachment, and cardiovas-
cular disease. Although statistical comparisons between the full
NIIPPU case sample and persistent NIIPPU cases were not per-
formed, autoimmune comorbidities and risk factors for ocular
complications tended to be more frequent in the persistent sample.
Development of Ocular Complications
Mean follow-up duration in the study period was approximately 5.6
years for cases with NIIPPU and 6.9 years for controls. Overall, 58%657
Table 3. Autoimmune Comorbidities and Risk Factors for Ocular Complications at Baseline
Comorbidities and Risk Factors
Full Noninfectious Intermediate
Uveitis, Posterior Uveitis,
or Panuveitis Sample
Persistent Noninfectious Intermediate
Uveitis, Posterior Uveitis,
or Panuveitis Sample
Cases (n ¼ 1769) Controls (n ¼ 1769) Cases (n ¼ 302) Controls (n ¼ 302)
Charlson comorbidity index score, mean (SD)* 0.9 (2.0)y 0.2 (0.8) 0.9  1.8y 0.2  0.7
Select autoimmune comorbidities, no. (%)z 203 (11.5)y 46 (2.6) 89 (29.5)y 7 (2.3)
Spondyloarthritis 36 (2.0)y 8 (0.5) 14 (4.6)x 1 (0.3)x
Sarcoidosis 43 (2.4)y 1 (0.1) 22 (7.3)y 0 (0)y
Behçet’s syndrome 1 (0.1) 0 (0) 0 (0) 0 (0)
Multiple sclerosis 32 (1.8)y 5 (0.3) 5 (1.7) 1 (0.3)
Systemic vasculitis 24 (1.4)y 2 (0.1) 12 (4.0)x 2 (0.7)x
Inﬂammatory bowel disease 22 (1.2)x 9 (0.5) 8 (2.6)x 1 (0.3)x
Vitiligo 0 (0) 0 (0) 0 (0) 0 (0)
Systemic lupus erythematosus 11 (0.6) 4 (0.2) 5 (1.7)x 0 (0)x
Sjögren’s syndrome 5 (0.3) 2 (0.1) 2 (0.7) 1 (0.3)
Relapsing polychondritis 4 (0.2) 2 (0.1) 3 (1.0) 1 (0.3)
Rheumatoid arthritis 38 (2.1)y 11 (0.6) 21 (7.0)y 0y
Psoriasis 13 (0.7) 11 (0.6) 5 (1.7) 1 (0.3)
Select risk factors for ocular complications, no. (%)jj
Disorders of refraction and accommodation 53 (3.0)x 29 (1.6) 6 (2.0) 6 (2.0)
Age-related macular degeneration 25 (1.4)y 2 (0.1) 5 (1.7) 0 (0)x
Corneal complications 23 (1.3)x 6 (0.3) 5 (1.7) 2 (0.7)
Diabetes, including diabetic retinopathy 190 (10.7)y 106 (6.0) 34 (11.3) 20 (6.6)x
Vitreous degeneration/detachment 41 (2.3)y 1 (0.1) 8 (2.6) 0 (0)y
Hypothyroidism 102 (5.8)x 56 (3.2) 16 (5.3) 12 (4.0)
Cardiovascular disease 196 (11.1)y 120 (6.8) 38 (12.6) 18 (6.0)x
Hypertension 301 (17.0)y 214 (12.1) 53 (17.5) 39 (12.9)
Metabolic syndrome 3 (0.2) 3 (0.2) 0 (0) 0 (0)
Migraine 34 (1.9) 24 (1.4) 10 (3.3) 4 (1.3)
Retinal vein occlusion 14 (0.8%)x 1 (0.1%) 2 (0.7) 1 (0.3%)
Injury to the eye 21 (1.2%)x 4 (0.2%) 6 (2.0) 1 (0.3%)
SD ¼ standard deviation.
*The 17 conditions included in the Charlson comorbidity index were identiﬁed using International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation diagnosis codes.47
yP  0.0001 versus controls from McNemar’s tests for comparisons of categorical variables and Wilcoxon signed-rank tests for comparisons of continuous
variables.
zComorbidities were deﬁned using International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation codes.
xP < 0.05 versus controls from McNemar’s tests for comparisons of categorical variables and Wilcoxon signed-rank tests for comparisons of continuous
variables.
jjRisk factors and other causes relevant to each ocular complication were based on a literature review and deﬁned using International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation codes (see Table 1, available at www.aaojournal.org).
Ophthalmology Volume 123, Number 3, March 2016of cases and 17% of controls had ocular complications during the
study period (P < 0.0001; Fig 2A). Cataract was the most common
ocular complication that developed during the study period (25%
vs. 9%), followed by visual disturbances (23% vs. 6%), retinal
disorders (23% vs. 1%), glaucoma (15% vs. 6%), retinal
detachment (9% vs. 0.6%), and blindness or low vision (4% vs.
0.3%). In the Kaplan-Meier survival analyses and the adjusted Cox
proportional-hazards regression models, the risk for developing any
ocular complication was signiﬁcantly greater for NIIPPU cases versus
controls, with an overall adjusted HR of 5.2 (P < 0.001; Fig 2B).
From Kaplan-Meier survival analyses, the estimated 1-year unad-
justed risk for any ocular complication was 45% for cases versus 7%
for controls, whereas the estimated 10-year risk for any ocular
complication increased to 75% and 37%, respectively. The estimated
1-, 5-, and 10-year risks of any ocular complication for persistent
NIIPPU cases versus controls were 55% versus 5%, 83% versus 27%,
and 88% versus 49%, respectively (Fig 3).
For each of the individual complications studied during
the entire study period, results from the Kaplan-Meier survival
analyses and the adjusted Cox proportional-hazards
regression models are depicted in Figure 4 (available at658www.aaojournal.org). For cataract (Fig 4A), cases were
signiﬁcantly more likely to demonstrate this complication
compared with controls, with an adjusted HR of 3.2. The
estimated 1-year unadjusted risk for cataract was 14% for cases
versus 3% for controls, the estimated 5-year risk was 35% for
cases versus 13% for controls, and the estimated 10-year risk was
48% for cases versus 25% for controls. Additionally, cases were
signiﬁcantly more likely to experience visual disturbance than
controls, with an adjusted HR of 4.8 (Fig 4B). The 1-, 5-, and 10-
year unadjusted probabilities for developing visual disturbance in
cases were 16%, 29%, and 39%, respectively, compared with 2%,
9%, and 14% for controls. Similarly, the risk of glaucoma
developing was signiﬁcantly greater for cases versus controls,
with an adjusted HR of 2.7 (Fig 4C). The 1-year unadjusted risk
for glaucoma was 10% for cases versus 2% for controls,
increasing to 26% for cases and 13% after 10 years. Cases also
had signiﬁcantly greater risks of retinal disorder (Fig 4D), retinal
detachment (Fig 4E), and blindness or low vision (Fig 4F)
developing compared with controls; however, the event counts
for these complications in the control group were too small to
estimate stable HRs.
A B
Figure 2. Overview of ocular complications in cases with noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIIPPU) versus controls. A,
Bar graph showing the percentages of patients who experienced ocular complications during the study period. B, Survival analysis for time to any ocular
complication. *Hazard ratios (HRs) and 95% conﬁdence intervals (CIs) were estimated from adjusted Cox regression analyses.
Dick et al  Ocular Complications in Noninfectious UveitisHazard ratios from adjusted Cox regression analyses for the
persistent NIIPPU analysis indicate signiﬁcantly greater risk (all
P< 0.001) for any ocular complication (HR, 8.9), visual disturbance
(HR, 8.1), cataract (HR, 6.2), or glaucoma (HR, 4.2) in persistent
cases versus controls (Table 4). Kaplan-Meier survival curves
estimating risk of and time to each individual ocular complication
for the persistent NIIPPU population are provided in Figure 5
(available at www.aaojournal.org).Discussion
The chronic inﬂammation resulting from untreated or
poorly controlled uveitis is a major cause of visual disability,Figure 3. Survival analysis for time to any ocular complication for persistent n
cases versus controls. *Hazard ratios (HRs) and 95% conﬁdence intervals (CIs)ocular complications, and potential blindness.4,5,7,8,15,18,22
Moreover, the potential that patients with uveitis will
experience a permanent sight-threatening outcome is
underrecognized.16,50 In this study, we conﬁrmed the asso-
ciation between uveitis and ocular complications such as
glaucoma, cataract, visual disturbance, blindness or low
vision, retinal detachment, and retinal disorders including
macular edema, with a focus on NIIPPU in a large sample of
patients being treated in real-world clinical practice. Further,
it should be noted that the lack of differences among dis-
orders of refraction and accommodation in our analyses
suggests that there is indeed an increased risk of ocular
complications associated with uveitis and that theseoninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIIPPU)
were estimated from adjusted Cox regression analyses.
659
Table 4. Risk of Developing Ocular Complications in Patients
with Persistent Noninfectious Intermediate Uveitis, Posterior
Uveitis, or Panuveitis
Ocular Complication
Hazard
Ratio*
95% Conﬁdence
Interval P Value
Any ocular complication 8.9 7.1e11.0 <0.001
Visual disturbance 8.1 5.9e11.2 <0.001
Cataracts 6.2 4.8e8.0 <0.001
Glaucoma 4.2 3.0e5.9 <0.001
Blindness and low visiony d d d
Retinal detachmentsy d d d
Retinal disordery d d d
*The hazard ratios represent the risk for persistent noninfectious inter-
mediate uveitis, posterior uveitis, or panuveitis patients relative to controls.
yHazard ratios were not calculated for blindness or low vision, retinal de-
tachments, or retinal disorders because of low event counts.
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visits and coding. In addition, we assessed whether there
were any morbidity changes in patients with chronic uveitis
by estimating the risk of ocular complications in a more
severe subset with persistently active NIIPPU, according to
the Standardization of Uveitis Nomenclature guidelines.9 To
identify persistent cases, we assumed that prolonged
treatment was required for chronic disease or to maintain
remission; therefore, persistent cases were required to have
chronic disease (deﬁned as duration 90 days) and to be
receiving treatment for NIIPPU.9 These data suggest that
there is a high unmet need for treatments that reduce the
occurrence of ocular complications in these patient
populations, particularly considering that other studies
have reported unacceptable corticosteroid maintenance
doses of up to 40 mg daily in patients with uveitis.8,16
This study reports the high risk of ocular complications
in patients with NIIPPU in a large population representative
of privately insured, employed United States patients. A
prior study evaluated costs and ocular comorbidities in
privately insured patients receiving corticosteroids, immu-
nosuppressants, or biologics for uveitis; however, those re-
sults are difﬁcult to compare with those of the present study
because the prior analysis included patients with anterior
uveitis.28 Compared with anterior disease, which is more
common and also can give rise to complications such as
cataract, macular edema, and glaucoma,8,15,16 NIIPPU
carries a greater morbidity and poorer prognosis. This
excess morbidity is not exclusively the result of the systemic
treatment required; it also results because the disease often is
associated with underlying autoimmune disorders and has a
higher prevalence of irreversible sight-threatening patho-
logic features.8,10,14,15,17,18,28 In this study, we found that
cases with NIIPPU had signiﬁcantly greater comorbidity
compared with controls. After adjusting for these differ-
ences, cases had signiﬁcantly greater risks of each of the
studied ocular complications developing. Thus, even when
NIIPPU is associated with systemic disease, the ocular
disease alone independently gives rise to complications and
necessitates treatment to prevent morbidity. These ocular
complications may add signiﬁcantly to the overall economic660burden of the disease, for direct medical costs related to the
treatment of ocular complications would be expected (i.e.,
more ophthalmologist visits) as well as indirect costs asso-
ciated with loss of work productivity and early retirement
(e.g., loss of functional independence and ability to drive).
The economic burden of ocular complications in patients
with NIIPPU represents an important topic for future
research. More recently, and although it is not possible to
compare directly with the present study, reports from ter-
tiary uveitis referral centers in the United Kingdom have
demonstrated outcomes in large patient numbers; together,
the United Kingdom studies corroborate the burden of dis-
ease, not least through demands for health care re-
sources.8,15 Because the course of disease often is persistent,
residual damage occurs despite expert care in combination
with the high need for pharmacologic therapy (including
corticosteroid dependence and use of second-line immuno-
suppressant agents).
Strengths of this analysis include that it was based on
data from privately insured individuals covered by a large
set of companies with locations across the United States in a
wide range of industries and occupations. Moreover, the age
distribution of the NIIPPU sample is representative of the
natural history of the disease, in which the diagnosis typi-
cally occurs during the working years, with peak onset in the
ﬁfth decade of life.1,6e8,28 This sample includes claims from
both community and tertiary care centers rather than a single
center, supporting its generalizability. By design, the control
cohort had no history of uveitis or baseline ocular comor-
bidities; however, the control population reduced ascer-
tainment bias in that underlying comorbidities not related to
uveitis, such as hypertension, cardiovascular disease, dia-
betes, and autoimmune comorbidities, were present.
Limitations of this study include those common to
retrospective analyses of health care claims data. For
example, it is possible that there were errors in the database
or omission of relevant claims, and details of the physicans’
clinical judgment were not available to conﬁrm the accuracy
of the diagnostic coding. However, these types of limitations
are likely to affect the case and control cohorts equally and
are unlikely to bias the results or substantially alter inter-
pretation of the ﬁndings. Because uveitis is a rare disease,
even if a large number of cases were misclassiﬁed as con-
trols, the misclassiﬁcations would have a relatively small
effect on the risk ratios and other outcomes measured
because any effect would be diminished by the large number
of controls. Although the age range (18e64 years) of the
study population largely eliminates age-related macular
degeneration from the control group, which may change the
relative risk of retinal complications, this limitation is ex-
pected to have a minimal effect on the outcomes reported in
this study because the age at presentation of uveitis among
the working-age population typically is younger than that of
age-related macular degeneration. When assessing whether
there were any morbid changes among the subgroup of
persistent uveitis cases, it is important to keep in mind that
the methodology used may have introduced 2 opposing
biases related to treatment: the ﬁrst, in which patients with
more severe disease are more likely to be treated and fol-
lowed up, thereby increasing the estimated risk of
Dick et al  Ocular Complications in Noninfectious Uveitiscomplications; and the second, in which patients with more
severe disease are treated effectively, thereby decreasing the
estimated risk of complications. In addition, the study
sample included only privately insured employees and their
dependents; hence, it may not be reﬂective of other pop-
ulations such as the general United States population, the
uninsured or Medicaid populations, or the elderly. Finally, it
should also be noted that the reported associations may be
underestimated because patients with major ocular problems
may be unable to work, and therefore no longer have private
medical insurance as a result of disability. Because this
study was retrospective, the ﬁndings should be interpreted
as an association of what seems to be a greater risk of ocular
complications in the NIIPPU cohort rather than a causal
association. Nevertheless, longitudinal studies of claims
data can be a useful means of assessing the burden of less
common diseases such as uveitis, particularly because it is a
heterogeneous condition that may be diagnosed by a variety
of health care providers.
In conclusion, patients with NIIPPU were 5 times more
likely and patients with persistent NIIPPU were 9 times
more likely to experience an ocular complication compared
with matched controls who did not have uveitis. Cataract,
visual disturbance, and retinal disorder, including macular
edema, were the most common ocular complications that
developed during the study period. These ﬁndings highlight
the importance of pursuing optimal treatment initiatives to
reduce the burden of ocular-related complications in patients
with NIIPPU.
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